Wang Cong, Wang Peiguo, Ouyang Huaqiang, Wang Jing, Sun Lining, Li Yanwei, Liu Dongying, Jiang Zhansheng, Wang Bin, Pan Zhanyu
1 Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
2 Fudan University Shanghai Cancer Center, Shanghai, China.
Integr Cancer Ther. 2018 Jun;17(2):444-450. doi: 10.1177/1534735417725578. Epub 2017 Sep 4.
To estimate the efficacy of traditional Chinese medicine (Chining decoction, CHIN) for radiation-induced oral mucositis in patients with head and neck cancer.
From May 2014 to December 2015, 70 consecutive patients were randomly assigned to receive CHIN (treatment group) or recombinant human epidermal growth factor (rhEGF) spray (control group) at a 1:1 ratio. CHIN was administered to treatment group from the first day of radiotherapy until the completion of radiotherapy. Simultaneously, the rhEGF spray was administered to control group on the oral mucosa of irradiated area. The clinical benefit was determined by gradation of mucositis (Common Terminology Criteria for Adverse Events v4.0), oral pain, and xerostomia (visual analysis scale) for each week during radiotherapy. Body mass index was evaluated before and after radiotherapy.
Patients in the treatment group had prominent remission of oral pain and grade of mucositis on each observing point compared with those in control group ( P < .01). Xerostomia was decreased notably in treatment group compared with control group ( P < .01). Body mass index in the treatment group exhibited advantage over control group after radiotherapy, but there was no statistical significance (19.8 ± 3.26 vs 18.8 ± 2.5 kg/m, P = .153, >.05).
CHIN presented an obvious advantage in preventing radiation-induced oral mucositis compared with rhEGF spray.
评估中药(中药汤剂,CHIN)对头颈部癌患者放射性口腔黏膜炎的疗效。
2014年5月至2015年12月,70例连续患者按1:1比例随机分配接受CHIN(治疗组)或重组人表皮生长因子(rhEGF)喷雾剂(对照组)。治疗组从放疗第一天开始服用CHIN直至放疗结束。同时,对照组在照射区域的口腔黏膜上使用rhEGF喷雾剂。通过放疗期间每周的黏膜炎分级(不良事件通用术语标准v4.0)、口腔疼痛和口干(视觉分析量表)来确定临床获益。放疗前后评估体重指数。
与对照组相比,治疗组患者在每个观察点的口腔疼痛和黏膜炎分级明显缓解(P <.01)。与对照组相比,治疗组的口干明显减轻(P <.01)。放疗后治疗组的体重指数优于对照组,但无统计学意义(19.8±3.26 vs 18.8±2.5 kg/m²,P =.153,>.05)。
与rhEGF喷雾剂相比,CHIN在预防放射性口腔黏膜炎方面具有明显优势。